Dupilumab: tested on its own
118 studies: no other medicine in its arm. Page 2 of 2. Open to participants first (21), then studies with results posted, then the rest; newest registration first within each.
- Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)CompletedNCT04362501Phase 2Report a problem
- The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab TreatmentCompletedNCT04358224Phase 4Report a problem
- Clinical Trial to Evaluate Efficacy and Safety of Dupilumab in Localized SclerodermaCompletedNCT04200755Phase 2Report a problem
- Dupilumab Impact on Skin Resident Memory T CellsStatus unknownNCT03983460Not applicableReport a problem
- Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical CorticosteroidsCompletedNCT03861455Phase 2Report a problem
- Cholinergic Urticaria - Efficacy of DupilumabCompletedNCT03749148Phase 2Report a problem
- Dupilumab in Chronic Spontaneous UrticariaCompletedNCT03749135Phase 2Report a problem
- Investigating Dupilumab's Effect in Asthma by GenotypeActive, not recruitingNCT03694158Phase 4Report a problem
- Effect of Dupilumab on Sleep Apnea in Patients With RhinosinusitisTerminatedNCT03675022Early Phase 1Report a problem
- Dupilumab for Aspirin-exacerbated Respiratory DiseaseCompletedNCT03595488Phase 2Report a problem
- Study of Dupilumab Auto-injector Device When Used by Patients With Atopic DermatitisCompletedNCT03050151Phase 1Report a problem
- Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)CompletedNCT02612454Phase 3Report a problem
- Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male SubjectsCompletedNCT01537653Phase 1Report a problem
- Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy SubjectsCompletedNCT01537640Phase 1Report a problem
- Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy VolunteersCompletedNCT01484600Phase 1Report a problem
- Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic DermatitisCompletedNCT01385657Phase 1Report a problem
- Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic DermatitisCompletedNCT01259323Phase 1Report a problem
- Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy VolunteersCompletedNCT01015027Phase 1Report a problem